Man Group’s Accelerate Diagnostics AXDX Stock Holding History

Man Group’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Hold	0	–	–	–	2007
2020 Q1	–	Sell	-1,326	Closed	-$224K	–	1609
2019 Q4	$224K	Buy	+1,326	New	+$219K	﹤0.01%	1743
2019 Q2	–	Sell	-990	Closed	-$208K	–	1882
2019 Q1	$208K	Buy	+990	New	+$186K	﹤0.01%	1876
2018 Q4	–	Sell	-1,365	Closed	-$313K	–	1917
2018 Q3	$313K	Buy	+1,365	New	+$302K	﹤0.01%	1937

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Man Group's AXDX Position: Q2 2022 in Review

Man Group held its Accelerate Diagnostics (AXDX) position steady in Q2 2022 at 0 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

Man Group first reported a position in AXDX in Q3 2018 and has held it in 3 quarters since. The position peaked at $313K in Q3 2018. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

Man Group held 0 shares of Accelerate Diagnostics worth $10K as of Q2 2022.
Man Group left its Accelerate Diagnostics share count unchanged in Q2 2022.
Accelerate Diagnostics made up ﹤0.01% of Man Group's portfolio in Q2 2022, its #2007 holding.
Man Group first reported a position in Accelerate Diagnostics in Q3 2018 and has held it in 3 quarters since.
Man Group's Accelerate Diagnostics position peaked at $313K in Q3 2018.
74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.